WordNet

immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum
the 10th letter of the Roman alphabet (同)j

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 日本脳炎：疫学、診断、治療、および予防 japanese encephalitis epidemiology diagnosis treatment and prevention
2. 旅行者のための予防接種 immunizations for travel
3. 予防接種に対するアレルギー反応 allergic reactions to vaccines
4. 節足動物媒介性脳炎 arthropod borne encephalitides
5. 妊娠中の予防接種 immunizations during pregnancy

Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.

Chokephaibulkit K1, Houillon G2, Feroldi E3, Bouckenooghe A4.
Expert review of vaccines.Expert Rev Vaccines.2016 Feb;15(2):153-66. doi: 10.1586/14760584.2016.1123097. Epub 2015 Dec 9.
JE-CV (IMOJEV®, Sanofi Pasteur, France) is a live attenuated virus vaccine constructed by inserting coding sequences of the prM and E structural proteins of the Japanese encephalitis SA14-14-2 virus into the genome of yellow fever 17D virus. Primary immunization with JE-CV requires a single dose of
PMID 26588242

Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.

Kim DS1, Jang GC, Cha SH, Choi SH, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Bang J, Naimi Z, Bouckenooghe A, Bosch-Castells V, Houillon G.
The Pediatric infectious disease journal.Pediatr Infect Dis J.2016 Feb;35(2):e60-4. doi: 10.1097/INF.0000000000000967.
BACKGROUND: This study evaluated the effect of a booster vaccination of a new, live attenuated, Japanese encephalitis chimeric vaccine (JE-CV). Previously this vaccine has been used as a booster 12 months after priming with an inactivated vaccine and at >24 months after priming with the same JE-C
PMID 26535878

Japanese Encephalitis Vaccines: WHO position paper, February 2015 - Recommendations.

Who.
Vaccine.Vaccine.2016 Jan 12;34(3):302-3. doi: 10.1016/j.vaccine.2015.07.057. Epub 2015 Jul 29.
This article presents the World Health Organization's (WHO) recommendations on the use of Japanese Encephalitis (JE) vaccines excerpted from the WHO position paper on Japanese Encephalitis vaccines recently published in the Weekly Epidemiological Record [1]. This updated position paper on JE vaccine
PMID 26232543

Production of Japanese encephalitis virus-like particles using the baculovirus-insect cell system(CELL AND TISSUE ENGINEERING)

Yamaji Hideki,Segawa Maiko,Nakamura Masataka [他],Katsuda Tomohisa,Kuwahara Miwa,Konishi Eiji
Journal of bioscience and bioengineering 114(6), 657-662, 2012-12
… The production of a secreted form of Japanese encephalitis (JE) virus-like particles (VLPs) using the baculovirus-insect cell system was investigated. … A recombinant baculovirus that contained the JE virus (JEV) prM signal sequence and the genes encoding the precursor (prM) of the viral membrane protein (M) and the envelope glycoprotein (E) was constructed. …
NAID 110009578162

AN-P37 The production of swine cholera marker vaccine by serum free culture of insect cells infected with baculovirus(Section I Animal and Plant Cell Cultures)

Antibody Responses Induced by Experimental West Nile Virus Infection with or without Previous Immunization with Inactivated Japanese Encephalitis Vaccine in Horses

, , [他], , , , , , , , , ,
Journal of Veterinary Medical Science 71(7), 969-974, 2009
… A group of horses immunized with inactivated Japanese encephalitis (JE) vaccine (JE-Immune Group) and a group of non-immunized horses (Non-Immune Group) were infected with West Nile virus (WNV). …
NAID 130000134436